79/100
✓ Peer-reviewed
alzhub usefulness score 79 out of 100.
·
Brain
·
2025-02-03
Plasma %p-tau217WashU had the highest performance, with significantly higher AUCs than all the immunoassays (Pdiff < 0.007). 5 key findings →
Design: cohort
Participants: 998
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
79/100
✓ Peer-reviewed
alzhub usefulness score 79 out of 100.
·
Nature Aging
·
2025-03-28
Plasma p-tau217 and tau positron emission tomography (PET) are strong prognostic biomarkers in Alzheimer's disease (AD), but their relative performance in predicting future cognitive decline among cognitively unimpaired (CU) individuals is unclear. 2 key findings →
Design: cohort
Participants: 1,474
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Concentrations of amyloid-beta (Aβ)(42) in the CSF appeared to decline 25 years before expected symptom onset. 5 key findings →
Design: cross-sectional
Participants: 128
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
76/100
✓ Peer-reviewed
alzhub usefulness score 76 out of 100.
·
JAMA Neurology
·
2024-09-01
In BioFINDER-2, the mean (SD) age was 65.7 (14.4) with 261 females (52.7%). 3 key findings →
Design: cohort
Participants: 983
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
74/100
✓ Peer-reviewed
alzhub usefulness score 74 out of 100.
·
Nature medicine
·
2019-01-21
Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for various cerebral proteopathies. 2 key findings →
Design: cross-sectional
Participants: 187
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
74/100
✓ Peer-reviewed
alzhub usefulness score 74 out of 100.
·
Nature medicine
·
2024-02-21
With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying patients who could benefit from these treatments becomes critical. 1 key finding →
Participants: 1,422
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
74/100
✓ Peer-reviewed
alzhub usefulness score 74 out of 100.
·
JAMA neurology
·
2024-06-01
Of 236 eligible participants screened, 43 were excluded. 2 key findings →
Design: longitudinal study
Participants: 142
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
In this prospective cohort study, we included adults aged 40 years or older with subjective cognitive decline, mild cognitive impairment, or dementia, based on cognitive test results and clinical assessments, consecutively recruited at two memory clinics in Sweden, as part of the Swedish BioFINDER-2 study. 3 key findings →
Design: cohort
Participants: 572
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
72/100
✓ Peer-reviewed
alzhub usefulness score 72 out of 100.
·
JAMA Neurology
·
2025-11-01
Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. 5 key findings →
Design: cross-sectional
Participants: 2,916
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
72/100
✓ Peer-reviewed
alzhub usefulness score 72 out of 100.
·
JAMA
·
2024-10-01
The mean age was 74.2 years (SD, 8.3 years), 48% were women, 23% had subjective cognitive decline, 44% had mild cognitive impairment, and 33% had dementia. 2 key findings →
Participants: 307
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
70/100
✓ Peer-reviewed
alzhub usefulness score 70 out of 100.
·
Nature medicine
·
2026-02-19
Predicting not just if, but also when, cognitively unimpaired individuals are likely to develop onset of Alzheimer's disease (AD) symptoms would be useful to clinical trials and, eventually, clinical practice. 2 key findings →
Design: cohort
Participants: 603
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
70/100
✓ Peer-reviewed
alzhub usefulness score 70 out of 100.
·
JAMA network open
·
2022-04-01
These findings suggest that this blood biomarker test could allow for distinguishing individuals with brain amyloid-positive PET findings from individuals with amyloid-negative PET findings and serve as an aid for Alzheimer disease diagnosis. 4 key findings →
Design: cohort study
Participants: 249
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
69/100
✓ Peer-reviewed
alzhub usefulness score 69 out of 100.
·
JAMA neurology
·
2023-05-01
Higher eGFR was associated with increased levels of plasma p-tau217, p-tau181, Tau212-221, and Tau181-190 in individuals with cognitive impairment (cohort 1: R range, -0.24 to -0.59; P Conclusions and relevance In this study, CKD was associated with increased plasma levels of soluble tau, but for p-tau217 the associations were considerably lower than the association with Aβ positivity. 4 key findings →
Design: cross-sectional
Participants: 141
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
JAMA Neurology
·
2026-07-01
The BioFINDER-2 main cohort included 872 participants, with an additional 156 participants in the Knight ADRC cohort for independent validation. 2 key findings →
Design: cohort
Participants: 1,028
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
Nature medicine
·
2023-07-13
Aggregated insoluble tau is one of two defining features of Alzheimer's disease. 3 key findings →
Participants: 448
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
Neurology
·
2021-12-14
Plasma Aβ42/Aβ40 is a robust measure for detecting amyloid plaques and can be utilized to aid in the diagnosis of AD, identify those at risk for future dementia due to AD, and improve the diversity of populations enrolled in AD research and clinical trials. 3 key findings →
Participants: 465
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
The use of an amyloid clock enabled visualization and analysis of biomarker changes as a function of estimated years from symptom onset in sporadic AD. 1 key finding →
Design: cross-sectional
Participants: 118
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
64/100
✓ Peer-reviewed
alzhub usefulness score 64 out of 100.
·
JAMA neurology
·
2022-08-01
Among 300 participants with DS and a control group of 37 non-DS siblings, mean (SD) age was 45.0 (10.1) years, and 167 (49.6%) were men. 4 key findings →
Design: cross-sectional
Participants: 300
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Among cognitively normal participants with positive biomarkers, 34.4% developed cognitive impairment (Clinical Dementia Rating > 0) as compared to 8.4% of those with negative biomarkers. 2 key findings →
Design: longitudinal study
Participants: 720
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Studies evaluating the diagnostic test accuracy of plasma phosphorylated tau (p-tau) and amyloid beta (Aβ) tests (p-tau217, %p-tau217, p-tau181, p-tau231, and Aβ42/Aβ40) compared to reference standard tests (cerebrospinal fluid [CSF] AD biomarkers, amyloid positron emission tomography [PET], or neuropathology) in individuals with cognitive impairment (mild cognitive impairment or dementia) in specialized care settings were included. 4 key findings →
Design: meta-analysis
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
We enrolled a cohort of 1070 PSEN1 E280A mutation carriers and 1074 non-carriers with baseline assessments; of these participants, longitudinal measures (with a mean follow-up of 6 years) were available for 242 mutation carriers and 262 non-carriers. 1 key finding →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Disease-modifying therapies for Alzheimer's disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. 2 key findings →
Design: cross-sectional
Participants: 567
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
These findings suggest a benefit of MI plus omega 3 in positive blood amyloid subjects. 4 key findings →
Participants: 483
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
63/100
✓ Peer-reviewed
alzhub usefulness score 63 out of 100.
·
Brain
·
2025-10-03
Using the Swedish BioFINDER-2 cohort [n = 1702, 50.7% male, mean (standard deviation) age 68.4 (12.2) years], we compared the associations between tau/Aβ-PET load and fluid biomarkers alone versus biomarkers in a ratio with a reference protein (Aβ40 or np-tau) in univariate linear regression models. 5 key findings →
Design: longitudinal study
Participants: 1,702
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the need for biomarker confirmation of amyloid pathology. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 34,580 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.